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HumanObesity is a global health issue, as it is associatedwith increased risk of developing chronic conditions associated
with disorders of metabolism such as type 2 diabetes and cardiovascular disease. A better understanding of how
excessive fat accumulation develops and causes diseases of the metabolic syndrome is urgently needed. The
hypothalamic melanocortin system is an important point of convergence connecting signals of metabolic status
with the neural circuitry that governs appetite and the autonomic and neuroendocrine system controlingmetab-
olism. This system has a critical role in the defense of body weight and maintenance of homeostasis. Two neural
melanocortin receptors, melanocortin 3 and 4 receptors (MC3R andMC4R), play crucial roles in the regulation of
energy balance.Mutations in theMC4R gene are themost common cause ofmonogenic obesity in humans, and a
large literature indicates a role in regulating both energy intake through the control of satiety and energy expen-
diture. In contrast, MC3Rs have amore subtle role in energy homeostasis. Results fromour lab indicate an impor-
tant role for MC3Rs in synchronizing rhythms in foraging behavior with caloric cues and maintaining metabolic
homeostasis during periods of nutrient scarcity. However, while deletion of theMc3r gene inmice alters nutrient
partitioning to favor accumulation of fat mass no obvious role forMC3R haploinsufﬁciency in human obesity has
been reported. This article is part of a Special Issue entitled: Modulation of Adipose Tissue in Health and Disease.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Obesity is one of the major health issues faced by society in the 21st
century [1–3]. Over the last three decades, the number of persons catego-
rized as obese (body mass index of >30 kg/m2) has risen dramatically
in high-income countries and is now also increasing in developing
nations. The World Health Organization reported that more people die
as a result of conditions resulting from obesity compared to those associ-
ated withmalnutrition and being underweight. Obesity alters the body's
ability to regulate homeostasis and is almost invariably associated with
hyperinsulinemia indicating insulin resistance. Obesity is also associated
with increased risk of hyperlipidemia and hypertension [4]. Collectively,
these conditions are associated with increased prevalence of type 2 dia-
betes and cardiovascular disease [5]. Strategies for preventing as well as
attenuating obesity and its comorbidities are urgently needed.
Simply stated, preventing weight gain requires coordinating calorie
intake with energy requirements over time. The homeostatic control
of adiposity involves both peripheral and central mechanisms acting
in concert [6,7]. For historical reasons, the examination of pathways in
the central nervous system initially focused on the hypothalamus.ion of Adipose Tissue in Health
nd Aging, The Scripps Research
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l rights reserved.Lesions in the paraventricular (PVN), arcuate (ARC) or ventromedial
nuclei of the hypothalamus (VMH) had been observed nearly a century
ago to cause hyperphagia and obesity [8,9]. Mouse genetics had the key
role in providing leads in the identiﬁcation of speciﬁc neural substrates
involved. This review focuses on the central nervous melanocortin sys-
tem. An abundant literature has developed describing how this system
regulates energy balance. First ordermelanocortin neurons situated pri-
marily in the arcuate nucleus of the hypothalamus (ARC) are regulated
by many signals of metabolic status. The transmission of this informa-
tion about the energy status acts on target neurons expressing two
members of the melanocortin receptor family.
This review begins by providing an overview of the melanocortin
system and its integration in the neural network involved in the regula-
tion of body weight and metabolic homeostasis. It will then focus on
the current understanding of the role of neural melanocortin receptors,
the well-known MC4R and the poorly understood MC3R in preventing
obesity. Discussions on how the melanocortin system integrates signals
from the periphery have been provided in several recent reviews on
the regulation of melanocortin neurons that release the endogenous
ligands for the melanocortin receptors [10,11].
2. Overview of the melanocortin system
2.1. The melanocortin family: six endogenous ligands and ﬁve receptors
Themelanocortin receptors aremembers of theGprotein coupled re-
ceptor (GPCR) family. Stimulation bymelanocortin agonists is associated
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cyclase. Theﬁve receptors (MC1R toMC5R)were named in order of their
cloning [12–24]. The melanocortin receptors have a broad distribution,
being expressed throughout the body. MC3R and MC4R are referred as
the neural MCRs due to their high expression in the brain, although
they also exhibit expression in peripheral tissues [14,25,26].
The melanocortin ligands are produced by proopiomelanocortin
(POMC), a preprohormone post-translationally processed by pro-
hormone convertases (PC1/PC2) to produce the melanocortins,
β-endorphin (β-END), and β- and γ-lipotropin (LPH; Fig. 1). POMC
is expressed in the brain, anterior and intermediate lobes of the
pituitary, skin and many peripheral organs. The post-translational
processing of POMC varies between tissues. Adrenocorticotrophic
hormone (ACTH) is produced in the anterior lobe of the pituitary.
In the central nervous system, only the melanocyte stimulating
hormones (MSH), α-MSH, β-MSH and γ –MSH, are produced with
an exception in rodents that lack the N-terminal cleavage site for
β-MSH [27].
ACTH, α-MSH, β-MSH, and γ-MSH exhibit agonist activity, albeit
with variable degrees of speciﬁcity. When agonism is deﬁned as
stimulation of cAMP accumulation in cell-based assays, α-, β- and
γ-MSH all exhibit agonist activity in cell lines expressing MC1R,
MC3R,MC4R andMC5R. However, theMC2R is unique in showing afﬁn-
ity only for ACTH.While γ-MSH exhibits modest selectivity forMC3R, it
is still a functional agonist for the other MCRs (Fig. 1) [28,29]. There are
three different isoforms of γ-MSH (γ1-, γ2- and γ3-MSH) which may
have variable biological activity [30].
The melanocortin receptors are unique when compared to other
members of this family in that endogenous antagonists were also
identiﬁed soon after their cloning. Agouti and Agouti related peptide
(AgRP) interact with speciﬁc melanocortin receptors to inhibit the
activity of MSH. The expression of agouti in mouse is primarily found
in the skin, in the cells of the dermal papilla [31] consistent with its
role in the regulation of hair-pigment production by melanocyte, but
it is also present in testis [32]. The human homolog, agouti signaling
protein (ASIP), has been reported to be also expressed in the adipose
tissue [33]. AgRP is expressed in the brain, adrenal gland, testis, lung
and kidney [34].
Both agouti andAgRPwere initially described to function as selective
competitive antagonists. Agouti was reported to act as an antagonist
for the MC1R and MC4R, while AgRP was reported to function as anACTH
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Fig. 1. The melanocortin peptides and their receptors. Structure and processing of
POMC hormone precursor (A). Afﬁnity of MCRs for the melanocortins (B).antagonist for the MC3R and MC4R [35]. While it is true that agouti
and AgRP act as competitive antagonists that prevent binding of
MSH, subsequent studies indicated that binding of these peptides to
melanocortin receptors results in activation of signaling pathways.
Soon after its identiﬁcation, AgRPwas reported to exhibit inverse agonist
properties inhibiting the high level of basal activity ofMC4Rs [36,37] and
MC3Rs [38] in the absence ofα-MSH.More recently, it was reported that
AgRP could stimulate coupling of MC4R expressed in a hypothalamic
neuronal cell line (GT1-7) to theGi/o subunit [39]. Interestingly, the elec-
trophysiological characterization of the response of neurons to AgRP in
the ventromedial hypothalamus has also indicated the involvement of
Gi/o-dependent pathways [40]. The relevance of in vivo inverse agonism
of AgRP is supported by results showing that central administration
of AgRP to neuronal speciﬁc POMC deﬁcient mice induces a delayed
increase in food intake and reduction in oxygen consumption [41].
However, this ﬁnding has been questioned with no difference in the
obese phenotype of double Pomc−/−; Agrp−/− mice compared with
Pomc−/− mice [42,43]. Inverse agonism by agouti at the MC1R has
also been suggested to have a functional relevance as it is responsible
for the yellow coat color of obese Ay/amice [44,45].
A common feature of several GPCRs is the observation that agonist
binding promotes receptor internalization following the recruitment
of β-arrestins. The recruitment of β-arrestins and the consecutive
internalization of the neural MCRS are observed following binding of
either AgRP or α-MSH [46]. Collectively, these ﬁndings suggest that
MSH and AgRP function as biased agonists and that the regulation of
the coupling ofMC4R involves both stimulatory or inhibitory G proteins
[39,40,47]. It has also been proposed thatmelanocortin effect on energy
expenditure is mediated via Gs, whereas action on food intake involves
other signaling [48].
The development of resonance energy transfer techniques has
enabled the visualization of GPCR interactions. Much has been learnt
on GPCR dimerization/oligomerization, and this is now increasingly
accepted as a general phenomenon that results in changes in the bio-
chemical characteristics of GPCRs. Both neural melanocortin receptors
have been reported to form heterodimers with other GPCRs [49–53].
2.2. Anatomy of the central melanocortin system
The hypothalamic melanocortin system is a point of intersection
in the neurocircuitry connecting appetite and the autonomic and neu-
roendocrine control of metabolism with signals of metabolic status to
defend body weight. Within the brain, two different neuronal popula-
tions expressing POMC have been distinguished by their anatomical
site. The largest population is located in the hypothalamus, and more
speciﬁcally in the lateral part of the ARC. This population coexpresses
the cocaine amphetamine-related transcript (CART) [54]. A second
smaller population is located in the brainstem, in the nucleus of tractus
solitarii (NTS). The neuronal population expressing AgRP is restricted to
the medial ARC and co-expresses neuropeptide Y (NPY) [55,56]. The
pattern of the distribution of AgRP and POMC neuronal projections is
similar in the forebrain, however only POMC neuronsmay send projec-
tions to the brainstem [57].
The twodistinct neuronal populations described above are considered
to have opposite effects on energy homeostasis. POMC neurons via
release of MSH inhibit food intake, while AgRP neurons promote food
intake. The development of new techniques allowing remote control of
neuronal activity either via light-activated ion channels (optogenetic) or
via stimulation of “designer” GPCRs (DREADD, Designer Receptors
Exclusively Activated by Designer Drug) have helped to clearly establish
that acute stimulation of AgRP neurons is sufﬁcient to initiate feeding
[58,59]. On the other hand, photic stimulation of channel rhodopsin
expressed by POMC neurons decreases food intake [58]. Mice lacking
Pomc gene products are hyperphagic and obese [60–63]. AgRP over-
expressing mice are a mouse model of obesity [35,64]. Unexpectedly,
neonatal deletion of AgRP did not produce a lean phenotype [65].
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period was raised by the reexamination of the AgRP−/− mice at an
older age that suggested a lean phenotype at 6 month of age [66]. Further
studies have shown that postnatal ablation of AgRP neurons has modest
to dramatic consequences depending at least partially on the extent of
neuronal loss [67–70] that in the most severe cases leads to starvation
anddeath [69]. These results suggest compensatorymechanisms overrid-
ing the loss of AgRP in early development. The existence of compensatory
mechanisms for loss of AgRPwas revived recently by an obese phenotype
at 3 months of age in mice where the ablationwas performed during the
neonatal stage [71].
POMC and AgRP neurons have been described as “ﬁrst order”
neurons in that they are the primary targets of signals communicating
energy status, with responses reported for leptin [72–77], insulin
[78–81], ghrelin [82–85], serotonin (5-HT) [86–92] and glucose [93,94]
(Fig. 2). Among the signals of energy state, leptin has been the most
intensively studied. Leptin is a hormone secreted by adipose tissue in
proportion to fat mass, and thus reﬂects the body lipid content [95].
Despite a role in the periphery, it is well-accepted that its primary site
of action is the hypothalamus where its full-length receptor, LepRb, is
highly expressed in several regions including among the ﬁrst order neu-
rons [72,96]. Subsets of LepRb-expressing neurons located outside the
hypothalamusmay also account for leptin action on energy homeostasis
[97]. Activation of LepRb on POMC neurons is thought to trigger MSH
releasewhile on AgRP neurons it has an inhibitory effect. The population
of POMC neurons in ARC is heterogeneous in term of receptor expres-
sion, distinct subpopulations of POMC neurons express either LepRb
or the insulin receptor, InsR [98,99]; this suggests that signals of energy
state (leptin, insulin) are received by different subtypes of POMCneurons.
The release of MSH or AgRP activates second order neurons through
melanocortin receptors (Fig. 2). MC3R andMC4RmRNA are localized in
different nuclei of the brain [14,26,100–102]. MC4Rs show a broader
expression than MC3R being identiﬁed in around 100 brain nuclei. Its
highest expression is observed in the hypothalamus and the brainstem.
MC3Rs have a more restricted pattern of expression, and are expressed
in the hypothalamus and limbic structures. The highest levels of expres-
sion have been reported in the ARC, VMH, ventral tegmental area (VTA)
and the medial habenula (MHb) [14].
Second order neurons expressing MC4Rs include includes oxytocin,
thyrotropin-releasing hormone (TRH) and corticotrophin-releasing hor-
mone (CRH) synthesizing neurons in the PVN [102,103]. Preganglionic
neurons in the intermediolateral cell column (IML) receiving directARC
MC3R/MC4R
MC4R
Food intake, Glucose metabolism, 
Food anticipatory behavior, …
Energy 
expenditure, 
Glucose 
metabolism, 
Cholesterol 
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Fig. 2. The hypothalamic melanocortin system. POMC (red) and AgRP (green) neurons
in the ARC are referred as “ﬁrst order” neurons integrating information about the energy
state and relaying those information to “second order” neurons expressing MCRs.inputs from POMC ﬁbers [54] are another site of MC4R expression. Little
is known about the identity of MC3R expressing neurons. Nevertheless,
the MC3R is the only melanocortin receptor expressed by POMC and
AgRP/NPY neurons in ARC [57,104,105]. MC3R expressed by POMC
neurons have been proposed to have an auto-inhibitory role [75,106].
3. Genetic evidence: Mc3r−/− and Mc4r−/− mice studies reveal
roles in prevention of obesity
Theﬁrst study reporting a role for themelanocortin in the regulation
of food intake in 1986 suggested that central administration of α-MSH
or ACTH1-24 decreased food intake in rat [107]. The cloning of the
melanocortin receptors allowed for the development of melanocortin
analogs, and many subsequent studies have conﬁrmed and character-
ized the role of the melanocortin system in the regulation of feeding
behaviors and energy balance. Among the melanocortin analogs, the
melanocortin agonist analog MTII and agouti mimetic SHU9119 have
been the most frequently used. The initial description of their central
effect has underscored the tonic inhibitory role of neural melanocortin
receptors on feeding [108]. Their afﬁnity for both neural MCRs meant
that it was not possible to distinguish betweenMC3R andMC4R actions.
Compounds with selectivity for MC4R, such as HS024 which is a selec-
tive MC4R antagonist [109], have been developed. However, the lack
of MC3R selective analogs remains to be resolved. Genetic murine
models developed for the neural melanocortin receptors Mc4r [110]
and Mc3r [111,112] were a necessary and critical step shedding light
on the speciﬁc roles of these receptors in energy homeostasis. Results
from analyzing the phenotype of these knockouts suggest that both
neural MCRs are important for maintaining energy homeostasis. Mc3r
andMc4r have non redundant roles in the regulation of energy balance
as emphasized by the more severe obese phenotype associated with
loss of both receptors (double knock-out Mc3r-Mc4r) compared to
each single knockout mice [112].
3.1. Mc4r−/− mice
The connection between the Mc4r and the obese phenotype of Ay/a
(yellow agouti) was ﬁrst hypothesized following the observation that
agouti is a functional Mc4r antagonist [113]. Deletion of most of the
Mc4r coding region in mice was subsequently shown to produce a
similar obesity syndrome comprised of maturity-onset weight gain
and increased longitudinal growth [110].Mc4r−/−mice also exhibited
hyperphagia, hyperinsulinemia, hyperglycemia, and hyperleptinemia
relative to wild-type controls, with heterozygous carriers exhibiting
an intermediate phenotype [110]. However, the severe diabetes initially
observed in Mc4r−/−mice on a mixed background was not observed
following the back crossing of the null allele onto the C57BL/6J back-
ground [114,115], suggesting a signiﬁcant effect of genetic background.
Homozygous carriers of null mutations in the human population while
severely obese and hyperinsulinemic also do not exhibit frank type 2
diabetes, indicating that loss of this receptor does not cause diabetes
per se [116,117].
The Mc4r−/− mouse model has proven to be an essential tool in
experiments providing information on functional selectivity. A key
example was the ﬁnding by Marsh and colleagues that Mc4r−/−
mice do not exhibit reduced food intake following intracerebroven-
tricular injections of MTII, suggesting that MC4R are required for
this response [118]. They also found that Mc4r also partially mediates
the inhibitory effect of leptin on feeding, as the inhibitory effect of
leptin on food intake is attenuated inMc4r−/−mice [118]. The inter-
pretation of these experiments is complicated as obesity inMc4r−/−
mice results in severe leptin resistance. However, pair fed or young
non obeseMc4r−/−mice do exhibit a diminished sensitivity to leptin.
On an outbred background,Mc4r−/−mice also retain the hypophagic
response to leptin treatment and lose weight [119]. Moreover, leptin-
deﬁcient mice lacking functional Mc4rs (Lepob/Lepob;Mc4r−/−) also
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Lepobmice [120]. Leptin thus inhibits food consumption bymechanisms
independent of Mc4r. This could involve action of other neurotransmit-
ters released bymelanocortin neurons (e.g., GABA), aswell as actions on
non-melanocortin neurons.
The Mc4r−/− mouse model has also been used in experiments
that investigate the cause of obesity in this model. While hyperphagia
is an obvious mechanism, it is not the only cause. Only one study has
reported that hyperphagia, and not hypometabolism, is primarily
responsible for the early onset of obesity in Mc4r−/− mice [121].
However, pair fed Mc4r−/− mice still exhibit increased fat mass
[122]. Non pair fed Mc4r−/− mice consume less oxygen (suggesting
reduced metabolic rate) relative to wild-type controls at 8 weeks of
age before their body weight diverge. They also exhibit an increased
body weight before the appearance of hyperphagia, suggesting that
Mc4r is also involved in the regulation of metabolism [122]. Male
Mc4r−/− mice exhibit a reduced locomotor activity during the night
[122]. Moreover, when expressed as percent of bodyweight, the resting
metabolic rate ofMc4r−/−mice is reduced relative to age-matched or
weight-matched wild-type mice and is insensitive to MTII administra-
tion [123]. The Respiratory Exchange Ratio (RER) or respiratory quo-
tient, which is an indicator of substrate preference to fuel metabolism,
is increased in Mc4r−/− mice in the fed state suggesting reduced fat
oxidation [114,123,124].
MC4Rs are not required for sensing nutritional deﬁcits and the re-
bound response following a negative energy balance [125]. However,
Mc4rs play a role in adaption to changes in diet. Following introduction
of more palatable diets with higher fat content, wild-typemice respond
by reducing the gram quantity of food consumption in order to main-
tain an isocaloric intake. In contrast, an exacerbation of weight gain of
Mc4r−/−mice in response to these diets involves increased food con-
sumption. A concomitant increase in feed efﬁciency (weight gain per
kcal ingested) indicated that othermetabolic mechanisms are involved.
An increase in locomotor activity observed in wild-type mice at the
transition to a diet containing more fat was absent in Mc4r−/− mice.
A defect in diet-induced thermogenesis and a reduced fatty acid oxida-
tion suggested by a higher RER were also observed. Overall, Mc4r−/−
mice exhibit an impaired acute homeostatic response in situations
where amore palatable diet are presented [125], and also exhibit a pos-
itive fat balance in situations where dietary fat intake is increased using
deﬁned diets where the ratio of fat and carbohydrate content is altered
[114].
The development of new transgenic models based on the cre lox
system is helping to resolve the roles of different neuronal populations
expressingMC4Rs. The Lowell and Elmquist labs have engineered a “lox
stop lox” (LoxTB)Mc4r model, inserting a transcriptional blocker in the
5′ untranslated region of the Mc4r gene. Its removal by cre mediated
recombination allows restoration of Mc4r expression in discrete cell
populations [126]. The phenotype of the homozygous null Lox TB
MC4R mouse is identical to that early reported for Mc4r−/− mice,
and can be rescued by restoration of MC4R during embryogenesis. The
use of this model has conﬁrmed that the actions of neural Mc4rs are
sufﬁcient for governing energy homeostasis. Using the Sim1 promoter
to drive cre expression in PVN and medial amygdala neurons, they
observed thatMC4Rs expressed in those regions are sufﬁcient to rescue
hyperphagia associatedwith loss ofMC4Rwhich accounts for 60% of the
obese phenotype [126]. A restoration of the anorectic effect of MTII, but
not of its effect to stimulate energy expenditure was also observed in
Sim-Cre;LoxTB Mc4r mice. This elegant study describes a functional
divergence of melanocortin pathways in the control of food intake
and energy expenditure (Fig. 3). However, these results need to be
interpreted with caution. Post-natal knockdown of Mc4r in the adult
rat PVN by an AAV-mediated gene silencing results in hyperphagia
and excessive weight gain in response to high fat diet but did not alter
food intake and body weight on regular chow [127]. MC4Rs outside
the PVN in the hypothalamus and in the brainstem have also beenimplicated in the regulation of appetite [128]. Moreover, MTII adminis-
tered in the rat PVN stimulates energy expenditure [129]. MC4Rs
expressed in other regions may be involved in the regulation of calorie
intake; however MC4Rs in the PVN are sufﬁcient to only overcome the
loss of this receptor in other brain regions with respect to the control
of feeding behavior. The Lowell and Elmquist labs subsequently exam-
ined the role of MC4Rs expressed by sympathetic preganglionic neu-
rons in the IML, and have suggested that these receptors are required
for MC4R actions that result in altered energy expenditure and glucose
homeostasis (Fig. 3) [130]. More recently, they have shown that MC4R
agonists have opposite effects on the two components of the autonomic
nervous system, directly inhibiting the activity of parasympathetic
preganglionic neurons in the DMV and exciting the activity of sympa-
thetic preganglionic neurons in the IML (Fig. 3) [131].
3.2. Mc3r−/− mice
Mc3r−/−mice exhibit a mild obesity phenotype characterized by
increased fat mass, reduced lean mass and reduced body length
[111,112]. At six months of age, Mc3r−/−mice are hyperleptinemic as
well as a hyperinsulinemic but not hyperglycemic [112]. The role of
MC3Rs in the regulation of feeding behavior is unclear as emphasized
by the discrepancies concerning food intake data from Mc3r−/− mice.
They were initially described as hypophagic [112] or normophagic on
chow diets [111]. More recently, by using an automated system to mea-
sure food intake, a slight hyperphagia was observed during the day
under high fat diet [124] and hypophagia has been observed during the
night under low fat diet [132]. AgRP administered in the third ventricle
inMc4r−/−mice still increases food intake, althoughwith less profound
effect when compared to wild-type mice [133]. A similar tendency in
another study [134] suggests that AgRP could act via Mc3r to regulate
feeding behavior. High doses of MTII when given peripherally or
centrally in Mc4r−/− mice result respectively in reduced and
increased food consumption [135]. The partial anorectic response
of both Mc3r−/− and Mc4r−/− mice following central injection
of MTII and its abolition in the double knock-out add evidence for
non-redundant role of MC3R and MC4R in energy balance [136].
Furthermore, on an outbred background Mc3r−/− mice exhibit a
delayed anorectic response to leptin [119]. Whereas more studies and
the development of speciﬁc agonist/antagonist for Mc3r are needed
to takes off discrepancies aboutMC3Rs role in the regulation of food in-
take per se, their involvement in feed efﬁciency is indicated by their
increased fat mass in the absence of hyperphagia.
A recent study provides a potentialmechanism, amodest increase in
corticosterone levels in the morning during the nadir in the daily
rhythms, as amechanismexplaining the obese phenotype [137]. Anoth-
er possible factor contributing to the obese phenotype of Mc3r−/−
mice is reduced physical activity which has been observed in their
home cage or during the dark phase in cage equipped with wheel
[111,112,132,138,139]. Loss of MC3R has also been suggested to reduce
“non-resting” energy expenditure, the part of energy expenditure at-
tributable to ambulation and the thermic effect of feeding [138]. How-
ever, the role of reduced activity in the obese phenotype is difﬁcult to
assess, as a recent study suggested a minor role for home cage activity
in energy expenditure in mice not housed at thermoneutrality [140].
Higher RER values have also been reported forMc3r−/−mice indicated
altered whole body substrate preference that does not favor fat oxida-
tion [115,124]. Even here, however, discrepancy exists as a more recent
study reported a reduced RER [138].MC3Rs thus appear to have a role in
modulating whole body substrate preference; however the contribu-
tion of this function to the obese phenotype remains uncertain.
While the phenotype ofMc3r−/−mice in the chow fed condition
is mild, they are more prone to develop diet-induced obesity as illus-
trated by their excessive weight gain. This excessive fat accumulation
when the dietary fat content is high doesn't result from a defect in
diet-induced thermogenesis observed for the Mc4r−/− mice, and it
Fig. 3. Divergent pathways in MC4Rs-mediated regulation of energy homeostasis. POMC (red) and AgRP (green) neurons in the ARC send projections to the forebrain, while only
POMC neurons may send projections to the brainstem (DMV) and spinal cord (IML). MC4Rs (purple) expressed in the PVN are sufﬁcient to regulate satiety. MC4Rs expressed on
preganglionic neurons in the DMV have an inhibitory effect on parasympathetic tone, while in the IML they exert an excitatory effect on the sympathetic outﬂow.
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Fig. 4.MC3Rs are required for entrainment to caloric cues. Examples of double-plotted
actogram of wheel turns under a 12:12 light-dark cycle in wild-type (A) and loxTB
Mc3r (B) mice fed ad libitum for 17 days and provided once a day with a hypocaloric
meal for 19 days. The red line shows the time of food presentation.
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nism [124,125]. Loss of MC3R also impairs metabolic adaptation to
fasting [137]. Fasted Mc3r−/− mice fail to increase lipolysis and
also exhibit reduced activation of the hypothalamo–pituitary–adrenal
axis. The increase in orexigenic peptide within the hypothalamus is
also attenuated providing an explanation for the decreased food
consumption after reintroduction of the food following a fast [137].
Mc3r−/−mice exhibit attenuated adaptation to a restricted feeding
protocol. Food restriction entrains circadian rhythms independently of
the master clock located in the suprachiasmatic nucleus [141,142].
This phenomenon has been proposed to represent an optimization of
feeding behavior, ensuring peak vigilance when nutrients are available.
It is thought to involve a food entrainable oscillator that functions inde-
pendently of themaster clock. Restricted feeding or hypocaloric feeding
protocols are commonly used to determine the impact of genemutation
or pharmacological treatment on the ability of food cues to entrain
circadian rhythms [143]. They consist respectively of restraining food
availability to few hours or providing hypocaloric meals at 24 h inter-
vals during the light phase when mice are least active. Mice submitted
to these protocols adapt by increasingwakefulness in the hours preced-
ing food presentation and exhibiting food anticipatory activity (FAA),
characterized by a rise in activity prior to meal intake. Remarkably,
Mc3r−/− mice show impaired metabolic and behavioral adaptation
to such protocols [132,138,139,144–146].Mc3r−/−mice fail to exhibit
increased wakefulness before food presentation, although they will
awaken and consume food following its presentation [132]. FAA moni-
tored using running wheels and infrared beam breaks is reduced in
Mc3r−/− mice relative to controls [132,138,139] (Fig. 4). The same
outcome has been observed in absence of light cues when the mice
were placed under constant darkness [144]. In contrast, Mc4rs do not
seem to be required [132,146].
We recently developed the Lox TB model for MC3R and conﬁrmed
that rescuing expression in early embryogenesis recapitulate the
behavioral and metabolic phenotype of the Mc3r−/− mice. Unex-
pectedly, restoration using Nestin-Cre of MC3R expression in the
central nervous system had only partial consequence on the obese
phenotype associated with loss of MC3R. The increase fat mass, re-
duced lean mass as well as the exacerbation of diet induced obesity
were at best partially rescued [138].This result should be interpret
with caution, as Nestin-Cre mice exhibit a mild hypopituitarism
[147] which could lead to confounding effect. However, if reproduced
using other neural-selective Cre transgenics this ﬁnding could indi-
cate a previously underestimated role of peripheral MC3Rs in the
defense of body weight.
Rescuing MC3Rs in SF1-expressing neurons in VMH also has only
a slight effect on the obese phenotype under chow fed conditions,reducing fat mass. Analysis of data from indirect calorimetry suggests
an improved whole metabolism substrate preference but no effect
on locomotor activity. At the time of the study was started, the
VMH was considered as a valid candidate for the localization of the
food entrainable oscillator [148]. However, restoring MC3R expres-
sion in the VMH failed to rescue the defective adaptation to restricted
feeding associated with loss of MC3R. Our unpublished data suggest
that others MC3R expressed in the brain may be sufﬁcient as we ob-
served normal FAA in mice expressing MC3R in the nervous system
(NesCre LoxTB Mc3r). The characterization of neuronal populations
expressing MC3R taking part in this complex behavior should thus
provides insights into the neural circuitry involved in this behavioral
adaptation to restricted feeding.
4. Autonomic and endocrine functions regulated byMCRs in obesity
The autonomic nervous system regulates metabolic homeostasis
and cardiovascular function. Melanocortin neurons are involved in
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gest that MC4Rs are required for the acute regulation of autonomic
function in response to centrally administered melanocortin analogs,
with MC3Rs unable to compensate for loss of MC4Rs. MC4Rs are
expressed in brain areas known to have autonomic functions including
hypothalamic nuclei such as the PVN, the dorsomedial nucleus of the
hypothalamus (DMH), and extra-hypothalamic sites [26,101]. In the
dorsal motor nucleus of the vagus (DMV) and IML, autonomic pregan-
glionic neurons identiﬁed by Chat (choline acetyltransferase) mRNA
express Mc4r [101]. Viral tracing studies performed by Tim Bartness'
laboratory in Siberian hamsters have greatly contributed to the current
knowledge about the distribution along the neuroaxis of autonomic
neurons expressing MC4R projecting to the interscapular brown adi-
pose tissue (iBAT) [149] and white adipose tissue (WAT) [150]. Expres-
sion ofMC4R in neurons projecting to theWAT has also been conﬁrmed
lately in rat [151]. Additive evidences were provided by pharmacologi-
cal studies. Administration of MTII dose-dependently increases the
sympathetic tone to BAT, as well as renal and lumbar sympathetic
nerve activity. SHU9119 when given alone had no effect but is able to
block the sympathoexcitation effects of MTII and the leptin induced
increase in renal sympathetic nerve activity [152]. Finally, the renal
sympathoexcitatory action of MTII, leptin and insulin is blocked in
Mc4r−/−mice and attenuated inMc4r heterozygote mice [153].
4.1. Adaptive thermogenesis
Brown adipose tissue (BAT) is highly innervated by the sympathetic
nervous system and plays a crucial role in adaptive thermogenesis in
response to environmental challenges. Melanocortins modulate sympa-
thetic outﬂow to affect BAT metabolism [152]. Using Ucp1 mRNA as a
readout of sympathoexcitation to BAT, it has been shown that the stim-
ulatory effect of leptin are abrogated in rat when SHU9119 is adminis-
tered centrally [154] and in Mc4r−/− mice [119,122]. Impairment in
diet-induced thermogenesis has also been reported in Mc4r−/− mice
after transition to moderate fat diet [125]. BAT isn't involved as levels
of norepinephrine or its turnover in BAT were unaffected in wild-type
mice oneday after the introduction of themoderate fat diet. Consistently,
the increase in oxygen consumption attributable to diet-induced ther-
mogenesis in rats fed a cafeteria diet has been reported not to be deter-
mined by increased oxygen consumption by BAT [155,156]. Moreover,
the levels of Ucp1 mRNA in wild-type mice didn't differ between the
chow fed conditions and the high-fat diet conditions at thermoneutrality
[157]. Howeverthe involvement of BAT in diet-induced thermogenesis is
controversial as it has been reported that MC4Rs are required for acute
induction of UCP1 in BAT in response to increasing amount of fat in the
diet [158]. MTII administered directly in the PVN or in the subzone
incerta produces a rise in the iBAT temperature [149,159], whereas
HS024, a selective MC4R antagonist, has the opposite effect and inhibits
MTII action [159]. AgRP is also potent at regulating iBAT temperature
[160] and when administered in the DMH is able to blunt the thermo-
genic effect of MTII [161].
Beside regulating the activity of the autonomic nervous system,
the melanocortins also regulate the hypothalamic-pituitary-thyroid
(HPT) axis. Within the hypothalamus, α-MSH and AgRP ﬁbers inter-
act with TRH neurons in PVN [134,162]. MC4Rs are expressed by
TRH-synthesizing neurons [102,163], and α-MSH in vitro stimulates
Trh gene expression via activation of MC4R [163] and increases TRH
release from hypothalamic explants [164]. In vivo, central infusion
of α-MSH increases thyrotropin levels [164] and prevents fasting
induced suppression of pro-Trh geneexpression in the PVN [162]. Central
infusion of AgRP reproduces the hypothyroid state seen during starva-
tion, but had no effect on circulating T4 levels and Trh gene expression
inMc4r−/−mice [164,165].
Lately, the importance of Mc4r in the central regulation of thyroid
hormone metabolism during fasting has been questioned [166]. By
preventing obesity using pair-fed Mc4r−/− mice, they found thatNPY, but not MC4R, is needed for the fasting induced suppression of
the central axis [166]. Furthermore, they highlight a new role for
both MC4R and NPY signaling in the regulation of hepatic thyroid
hormone metabolism required to suppress TH levels during fasting
[166]. At baseline, Mc4r−/− mice have normal circulating T4 and
TSH levels [165,166] indicating that Mc4r are not required for the
basal function of the HPT axis. The ﬁrst order neurons also contact
TRH-synthesizing neurons in human [167]. MC4R mutation in human
has no impact on free thyroxin levels but a tendency in some patient
to have higher thyrotropin levels was observed [116].
4.2. Glucose homeostasis
Insulin resistance resulting in abnormally elevated plasmatic
glucose levels is a precursor for type 2 diabetes. Insulin produced by
the pancreas acts on glucose homeostasis via two mechanisms, sup-
pressing hepatic glucose production and enhancing glucose disposal.
Both mechanisms are modulated by the melanocortin system. Early
pharmacological studies using α-MSH and SHU 9119 demonstrated
an opposite effect mediated via MC4R on insulin action [168]. Central
blockade of MC3R/MC4R increases insulin levels and reduces insulin
action in skeletal muscle while increasing glucose utilization in WAT
[169]. Interestingly, the results from this study suggested increased
insulin signaling in WAT of young “pre-obese” Mc4r−/− mice. This
outcome suggests that MC4Rs can have markedly different effects
on insulin action in peripheral tissues that contribute to altered
“nutrient portioning” between tissues.
On a mixed genetic background, chow fed mice lacking MC4R
exhibit hyperinsulinemia and hyperglycemia [110,122,126,130,131]
while Mc3r−/− mice are normoglycemic [111,112]. The insulinemia
inMc3r−/−mice is however less robust, since they have been reported
to be either hyperinsulinemic [112,138] or normoinsulinemic [111,146]
in the fasted and fed states. These data suggest that MC4Rs are the
primarymodulators of glucose homeostasis in normal conditions. How-
ever, a failure of Mc3r−/− mice to maintain glucose homeostasis is
evident under extreme conditions triggered by increased dietary fat
consumption or restricted feeding [90,146]. Fasting hyperinsulinemia
is exacerbated by a very high content of fat in the diet in both
Mc3r−/− and Mc4r−/− male mice. Mc3r−/− mice have been pro-
posed as a potential model of obesity-induced insulin resistance. Never-
theless, the hyperinsulinemia triggered by high fat diet in Mc3r−/−
mice is moderate in comparison to Mc4r−/− mice, which show the
greatest glucose intolerance accompanied by a profound disturbance
of insulin receptor signaling [115].
As mentioned above, the severity of the insulin resistant phenotype
of pre-obeseMc4r−/−mice seems to depend on the strain background
[114,170]. Pair feeding of Mc4r−/− mice can normalize glucose and
insulin levels, suggesting an effect of hyperphagia and subsequently
severe obesity on the diabetic phenotype of Mc4r−/− mice [122].
Restricted feeding protocol through its association with weight loss
improved glucose tolerance in Mc4r−/− and Ay/a mice, however
Mc3r−/− mice become glucose intolerant, hyperglycemic and hyper-
insulinemic [146]. This insulin resistance is qualiﬁed as mixed since
the liver appears to respond normally to elevated insulin. Mc3r−/−
mice exhibit thus a uniquediabetic like phenotypeunder negative ener-
gy balance condition. Treatment of Mc4r−/− mice with non-selective
melanocortin receptors agonists also improves the hyperinsulinemia
suggesting the involvement of other melanocortin receptors in the
regulation of insulin sensitivity [171].
LoxTB MCR models have been used to deﬁne subsets of neurons
expressing MCRs that are involved in glucose homeostasis. The con-
tribution of MC4Rs expressed by pre-autonomic neurons in modulat-
ing glucose homeostasis has been suggested by studies using LoxTB
Mc4r mice. Previously it had been reported that MC4Rs mediate the
improvements in glucose homeostasis due to stimulation of 5HT2CR
expressed on POMC neurons which are known to project to the IML
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system reduces the hyperinsulinemia associated with loss of MC4R,
while rescue in the sympathetic nervous system is required to reduce
the hyperglycemia and increase glucose disposal [130]. In contrast,
deletion of MC4Rs only in cholinergic neurons increases insulin levels
suggesting that Mc4r mediated decrease in parasympathetic tone
reduce insulin secretion [131].
The central melanocortin system via activation of neural MCRs
has also been shown tomediate part of leptin action on glucose homeo-
stasis. In non diabetic rats, upregulation of gluconeogenesis by leptin
is dependent on activation of neural MCRs, while leptin mediated
downregulation of glycogenolysis involve other pathway [172]. More-
over, leptin antidiabetic actions require a functional melanocortin
system. Central blockade of MCRs in streptozotocin induced diabetic
rats blocked leptin mediated decrease in blood glucose. However,
stimulation of central MCRs is not sufﬁcient to mimic leptin action
on glycemia suggesting the interactions of multiple pathways in the
regulation of glucose homeostasis via leptin [173].
4.3. Nutrient partitioning and lipid metabolism
Both Mc3r−/− and Mc4r−/− mice exhibit increased fat mass
and adiposity (fat mass as a percent of body weight) compared to
wild-type mice. In situation where low fat diets are used, Mc3r−/−
andMc4r−/−mice have hypertrophied WAT and this is exacerbated
under high fat diet [174,175]. Both Mc3r−/− and pair-fed Mc4r−/−
mice show a higher feed efﬁciency, and in both models a higher RER
(at least on the C57BL/6J background) indicates reduced use of fat to
fuel metabolism [124]. This nutrient partitioning defect has also been
examined during pharmacological studies as central infusion of MTII
decreases fat pad weight beyond what can be accounted by a reduc-
tion of food intake [176]. Inversely, central blockade of MC3R/MC4R
increases fat mass in pair fed rats [169].
Considering the “fatty” phenotype of neural melanocortin null mice,
it is not surprising that the melanocortin system may regulate lipid
metabolism. Central blockade of MC3R/MC4R promotes lipogenesis
and triglycerides storage in WAT, independently of an effect on food
intake [169]. In contrast, central stimulation of MC3R/MC4R triggers
lipid mobilization in WAT [160,169]. The effects of central MC3R/MC4R
on lipid metabolism may be mediated via the sympathetic nervous
system, as suggested by the localization ofMC4Rs on autonomic neurons
projecting to WAT [150,151]. Moreover, blockade or stimulation of
central melanocortin receptors respectively decrease or increase the
sympathoexcitation to WAT in mice [169], and an increase in norepi-
nephrine turnover in some WAT depots follows central administration
of MTII [160]. The absence of an upregulation of triglycerides synthesis
in WAT following central MC3R/MC4R blockade in mice lacking all
three β-adrenergic receptors has elegantly conﬁrmed the role of the
sympathetic nervous system [169].
Central blockade ofMC3R/MC4R also alters lipidmetabolism in skel-
etal muscle and liver [169]. The increase in hepatic triglycerides content
following intracerebroventricular treatment with SHU9119 is at least
partially due to an upregulation of lipogenic enzyme gene expression
through the activation of SREBP-1c and PPARγ2 [177], while MTII has
the opposite effect in an insulin-independent manner [178]. Hepatic
lipid metabolism is also compromised inMc4r−/−mice which exhibit
an increased hepatic content in triglycerides [114]. Mc3r−/− mice
show no difference of fasting liver triglyceride content [174]. Consistent
with this last ﬁnding, no fatty liver disease was observed in Mc3r−/−
mice despite an increased adiposity. However, a recent study by our
group suggests an altered fatty acid metabolism and a possible fatty
liver phenotype inMc3r−/−mice [138].
The melanocortin system may also be involved in regulating
cholesterol metabolism through modulation of Mc4r signaling [179].
Elevated levels of cholesterol in the plasma, intestine and liver of
Mc4r−/− mice have been observed in Mc4r−/− mice [180], whereasMc3r−/− mice show normal plasmatic content of cholesterol [179].
Treatment by central infusion of the Mc3r/Mc4r antagonist SHU9119
increase circulating HDL cholesterol, independently of effect on food in-
take, while MTII infusion in the lateral ventricle produce the opposite ef-
fect. Central MC4R blockade affecting plasma cholesterol is vagus nerve
dependent, showing that melanocortin action on plasma cholesterol is
mediated via the autonomic nervous system [179].
4.4. Cardiovascular functions
Hypertension is one of the metabolic abnormalities associated with
obesity and can have major health consequences as this increases the
risk to develop cardiovascular diseases. Acute central administration
of SHU9119 or MTII has no consequence on heart rate and arterial pres-
sure [152], while several days of MTII infusion results in a rise of arterial
pressure [181] prevented by adrenergic blockade [182]. In contrast,
chronic blockade of MC3R/MC4R with SHU9119 reduced both arterial
pressure and heart rate [181,183] and prevented the hemodynamic
responses to leptin [183] through the blockade of MC4R signaling
[184]. Rats fed a high fat diet exhibit an increase in arterial pressure
and are still sensitive to the cardiovascular action of melanocortin re-
ceptors activation [185]. Administration of MTII directly in different
brain nuclei expressing MC4R and connected to the sympathetic out-
ﬂow (PVN, NTS, rostral ventrolateral medulla, parabrachial nucleus,
retrochiasmastic area) results in tachycardia [128]. In spite of marked
obesity, Mc4r−/− mice are not hypertensive and can exhibit lower
heart rate [184,186]. Very recently, further evidence for the involve-
ment of the sympathetic nervous system in Mc4r mediated control of
blood pressure have been provided; re-expression ofMC4R in cholinergic
neurons renders the LoxTB Mc4r mice hypertensive [131]. Mc3r−/−
mice are normotensive but can become hypertensive when fed a high
sodium diet, due to a failure to respond to the natriuretic actions of
γ-MSH [187]. Interestingly, the salt-sensitive hypertension is also accom-
panied by abnormal glucose metabolism [188]; the underlying mecha-
nism remains unknown but the authors proposed an involvement of
the autonomic nervous system [189].
Studies in humans also suggest an important role for humanMC4R
in blood pressure control [190–192]. Subcutaneous infusion of MC4R
agonist in humans leads to an increase in blood pressure and heart
rate [190]. MC4R deﬁciency in human is associated with a reduced
prevalence of hypertension [190]. In another study, heart rate and dia-
stolic blood pressure tend also to be lower in humans with MC4R
deﬁciency [191]. Muscle sympathetic nerve activity (MSNA) provides
a direct measure of central sympathetic outﬂow to the vasculature
and tends to be lower in MC4R deﬁcient humans. Interestingly, there
is an inverse correlation between MSNA with BMI and leptin levels in
humanMC4Rmutants [191]. Studies of humans and rodents thus con-
verge in suggesting the requirement of an intact MC4R for
obesity-induced hypertension.
5. Human studies: association ofMC4Rmutations with obesity and
a lack of a status quo for MC3R
Mutations affecting melanocortin ligands or their processing
(POMC, PC1) have been associated with obesity in humans [193], while
inversely a polymorphism in the AgRP gene has been linked to leanness
in humans [194]. The ﬁrst description of human with POMC deﬁciency
established the role of endogenous ligands of melanocortin receptors in
energy balance [195]. Humans lacking POMC gene products exhibit
an early-onset obesity, hyperphagia, red hair pigmentation and hyper-
cotisolemia due to the ACTH deﬁciency. While the altered pigmentation
results from the lack of agonism at the MC1R, the ACTH deﬁciency from
the absence of signaling at MC2R, bothMC3R andMC4R could contribute
to the obese phenotype observed. However, the cumulative human
data suggest a preponderant role for human MC4R in the regulation of
appetite and body weight. The studies of human mutations have also
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peptides in energy homeostasis. Indeed, mutations resulting in the fusion
of β-MSH and β-endorphin reducing the ability to activate the receptor
[196] or in the coding sequence of the POMC-derived peptides β-MSH
[197,198] impairing thebindingof biological activity of the neuropeptides
have shed light on a previously underestimated role for β-MSH in regula-
tion of energy homeostasis in humans. A mutation in α-MSH, reducing
the binding toMC4R and subsequently affecting its signaling,was present
in a lean family member, and was thus insufﬁcient to fully match the
criteria to be associated with obesity [197].
A year after the publication describing the Mc4r−/− mouse phe-
notype two frameshift mutations due to either a 4-bp deletion [199] or
a 4-bp insertion in the coding sequence of MC4R gene [200] that result
in a truncated receptor and severe obesity were found in humans.
Since those initial observations, over 150 MC4R variants have been
reported. MC4R mutations are indeed not so rare with a prevalence of
up to 5.8% in a cohort of 500 patients with severe childhood obesity
[116]. MC4R haploinsufﬁciency is the most common known form of
monogenic obesity. Consistently, a recent genome-wide association has
shown that common variants near MC4R exhibit the strongest associa-
tion with BMI after variants in FTO [201].
MC4R mutations can follow a dominant mode of inheritance of
morbid obesity but also recessive pattern of inheritance exists [202].
The phenotype of human with MC4R deﬁciency is reminiscent of the
mouse Mc4r−/− phenotype, i.e. severe obesity, increased adiposity,
hyperphagia, severe hyperinsulinemia, and an increased linear growth
[116,202]. Moreover, a gene dosage effect has also been observed in
humans since homozygous are more obese than heterozygous MC4R
mutants [116]. MC4R mutations have also been sometimes associated
with binge-eating in adults [203] but not always [204]. Hyperphagia
seems to be stronger in early childhood with persistent food-seeking
behavior as early as 6 months of age [116,202]. Interestingly, enhance-
ment in appetite appears evenmore pronounced in humanswith leptin
deﬁciency [116], as observed in mouse models [125], and consistent
with the mediation of the inhibitory effect of leptin on food consump-
tion by other neuropeptides than melanocortins. A MC4R polymor-
phism has also been associated with physical activity [205]. Resting
energy expenditure and diet-induced thermogenesis is not affected by
MC4R mutations [116,203] but the respiratory quotient in patient
withMC4R deﬁciency is higher relative to obese controls, indicating dif-
ference in the preference of substrate utilization in humans (reduced
fatty acid oxidation).
There are examples of heterozygous carriers of MC4R mutations
not being obese despite altered receptor function [206]. Indeed, muta-
tions of MC4R may not to be 100% effective at causing obesity. Humans
with MC4R variant retaining residual signaling capacity are less affected
than those with a complete loss of function [116]. Moreover, not all the
mutations associatedwith obesity trigger a loss of function, onemutation
(D90N) has been suggested to function via a dominant negative effect
leading to an impairment of Mc4r signaling due to heterodimerization
of mutated and wild-type receptors [49]. Some mutations do not seem
to alter the receptor function. The absence of consequence on MC4R
signaling can be questioned as in most case the inverse agonism/biased
agonism effect of AgRP was not tested. Interestingly, two variants
(Val103Ile and Ile125Leu) have instead been linked with a protection
against obesity [207,208]. The in vitro analysis of the mutated receptors
suggests a possible gain of function [209]. Insights about the molecular
mechanism of MC4R activation have recently been gained by the associ-
ation of functional characterization of human mutations with structural
modeling [210].
Recent in vitro data suggest that aminoglycoside antibiotics can
suppress MC4R nonsense mutations by allowing the incorporation
of a random amino acid at the mutated position [211,212]. However,
in vivo use of aminoglycoside in a mouse model with a nonsense mu-
tation of MC4R, recapitulating the phenotype of the Mc4r−/− mice,
have failed to show any effect on obesity [212]. Nevertheless, theadministration was subcutaneous and aminoglycoside have been
shown to have a marginal penetration rate into the brain. Treatment
of mice by central administration of aminoglycoside could lead to a
different outcome [212].
In contrast to MC4R, the pathogenic role of MC3R mutations in
human obesity is still unclear. One caveat of MC3R study in human
could be the methods used [213]. If we make the parallel with mouse
studies, it is tempting to speculate thatMC3Rmight not be clearly asso-
ciated with obesity as deﬁned by increased body weight but rather by
an increase in adiposity which is not correlated with the BMI for the
non obese subjects [213]. A link between MC3R and food intake is also
unclear in human since both reduction or increase have been reported
[214–216]. So far, two mutations of humanMC3R could be pathogenic,
Ile 183 Asn [214,217,218] and Ile 335 Ser [215]. Two commonmissense
variants (Val81Ile and Lys6Thr) initially reported not be associatedwith
obesity but marginally with higher fasting glucose and insulin levels
[219] were in later studies [214,216,220]. The analysis of homozygoty
for those variants revealed an effect on fat mass and insulin level
[214,216,220]. An ethnic effect could also explain part of the divergence
as signiﬁcant association ofMC3Rmutations resulting in a defective re-
ceptor with obesity were observed in French children and Italian adult
but not in North American adults [221,222].
Targeting neural melanocortin receptors to treat obesity remains a
tantalizing prospect [223]. However, a major limitation to targeting
this receptor has been the potential side effects associated with the
use of such a compound due to the pleiotropic effect of melanocortin
ranging from control of blood pressure, allodynia to satiety. Several
pharmaceutical companies have developed selective MC4R agonists.
To date, these compounds have failed due to modest effects on food
intake and weight loss [224] and/or undesired effect on blood pressure
[190]. A recent study reported in a diet induced obese non human
primate model a transient decrease in food intake accompanied by a
weight loss that persists over 8 weeks of treatment with a MC4R
agonist, BIM-22493. This compound appears promising since it doesn't
affect cardiovascular function [225]. A previous study in mice has char-
acterized the effect of BIM-22493 on energy homeostasis and found
that functional MC4R is required for weight loss but not for improved
glucose homeostasis [171], suggesting that targeting more MCRs than
MC4R might be beneﬁcial to treat obesity and its related disorders.
6. Conclusion and future directions
Over the last two decades, the melanocortin receptors have been
cloned and much has been learned on their critical roles in energy
homeostasis. Both MC3Rs and MC4Rs are expressed centrally and
play a role in energy balance. The fact that MC4R mutations have
been clearly associated with obesity in human explains at least in
part why more studies have focused on MC4R. We know now that
actions of MC4Rs on energy homeostasis are broad including control
of lipid and glucose metabolism. MC3Rs have a modest impact on
energy balance under normal conditions but their contribution to
homeostasis is fully expressed under extreme conditions like periods
of plenty or scarcity.
The new genetic models, LoxTB MCRs, developed recently offer a
unique tool to decipher the role of the different neuronal population
regulating energy homeostasis. The use of the LoxTB Mc4r model
has been useful for distinguishing divergent role of Mc4r expressing
neurons in energy balance. MC4Rs expressed in the PVN and amygdala
are sufﬁcient to orchestrate food intake while MC4Rs expressed in the
autonomic preganglionic neurons affect in an opposite manner sympa-
thetic and parasympathetic tones to regulate energy expenditure,
glucose homeostasis and blood pressure. The identity of MC4Rs critical
for the central control of lipid metabolism remains to be established. In
addition, our studies using the LoxTBMc3rhave begun to dissectMC3Rs
action on energy homeostasis and circadian rhythmicity. Restoration
of MC3R in the VMH improved metabolic homeostasis but was not
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intake associatedwith loss ofMC3R. Unpublished data fromour lab sug-
gest that other neuronal populations expressing MC3Rs are involved in
the expression of food anticipatory rhythms and further exploration
will be required to deﬁne the populations involved. Surprisingly, neural
MC3Rs are not sufﬁcient to rescue the exacerbation of weight gain
when the dietary fat intake is high. However, a caveat in drawing this
conclusion is that further studies using neural-selective Cre transgenes
is required as it is possible that the Nestin-Cre transgene failed to
restore normal MC3R expression in a small subset of neurons which
are critical for protecting against diet-induced obesity. However, these
observations nevertheless point out a functional divergence between
MC3Rs in the regulation of energy homeostasis, and underscore an
underestimated role for peripheral MC3Rs in the defense of body
weight. Future studies will clarify the function of the remaining subset
of MCRs expressing cells.Acknowledgements
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